Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913744 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
A Phase 2 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00913744 is a Phase 2 study that has completed, run by ThromboGenics. The registered enrollment target is 100 participants.
The verdict
NCT00913744, a Phase 2 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).
Interventions
- DRUG Sham injection
- DRUG Ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00913744
The ClinicalTrials.gov registry entry for NCT00913744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT00913744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00913744 about?
NCT00913744 is a clinical study titled "Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion". This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical...
What is the current status of trial NCT00913744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2010-01. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00913744?
The interventions under investigation include: Sham injection (DRUG), Ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT00913744?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.